New treatments for dry eye disease that deliver lipids to the ocular surface are designed to more closely mimic the important tear film lipid layer at the air-water interface in the eye. The range and effectiveness of lipid-based products to treat dry eye disease, including liposome lid sprays, emulsion eye drops, lipid nanoparticles, and lipid-drug conjugates are examined in a new Review article published in Journal of Ocular Pharmacology and Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Ocular Pharmacology and Therapeutics website.
In the article entitled “Relevance of Lipid-Based Products in the Management of Dry Eye Disease,” Jean-Sébastien Garrigue and Mourad Amrane, Santen SAS (Evry, France), Marie-Odile Faure, Scientific Consulting For You (Paris, France), Juha Holopainen, University of Helsinki (Finland), and Louis Tong, Singapore Eye Research Institute, describe the favorable tolerability profile of lipid-based therapies. Lipid-based products offer advantages compared to water-based artificial tears. Not only can they provide immediate relief of symptoms, but they may also improve the structure and stability of the tear film lipid layer.
“This is a thorough and timely review addressing an emerging treatment modality for the painful disease of dry eye,” says Editor-in-Chief W. Daniel Stamer, PhD, Joseph A. C. Wadsworth Professor of Ophthalmology and Professor of Biomedical Engineering, Duke University, Durham, NC.